Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease

NCT06456593 is registered in ClinicalTrials.gov with Abivax S.A. as lead sponsor.

NCT NCT06456593
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06456593 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
Lead sponsor
Abivax S.A.
Phase
Phase 2
Overall status
Recruiting
Start date
October 30, 2024
Completion date
April 30, 2028
Enrollment
212 (estimated)
Sites
149

Conditions

As the registry lists them; a condition with its own page is linked.

moderately to severely active crohn disease